Candel Therapeutics, Inc. (CADL)
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
$12.78-1.46%
Close 2026-09-04 · 1-day change
NASDAQHealth CareBiotechnologySnapshot 2026-09-04
QuarterlyIQ Insights · CADL
What must go right, what could break, what the price assumes, and what evidence comes next.
The current health of the standing investment case.
Recent financial performance sits well below its industry cohort — worth keeping an eye on, though it has not freshly broken.
One-year growth currently built into the price, compared with our model's estimate.
| Measure | Marker shape | Value |
|---|---|---|
| Growth built into the price | circle | 81.8% |
| Our one-year growth estimate | diamond | Not available |
Growth built into the price is above our model estimate.
For each item: what to watch, what would become a concern, and what would make it less concerning.
A reporting-risk estimate, not a forecast of the stock-price response.
Historical relationships that met the evidence threshold. They do not prove cause or forecast a move.
Usually moved in the same direction.
Price observations: 365 days
Most sensitive to the broad stock market.
Based on historical daily prices through 2026-09-04.
Past price behavior in dollars on a $10,000 position. This does not measure permanent business risk.
How much price usually moves either way.
Use the underlying financial and sector pages to investigate the cause.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
A comparable growth gap is not available.
The one-year revenue growth assumption on Valuation.
Worth watching into the next print: this name operates in a high-miss-rate industry and has erratic recent earnings surprises. A fundamental tilt, not a price call.
Model as of 2026-09-04 · Compared with 398 industry peers · Company calendar date is not available
CADL — earnings miss
Dated 2026-08-13
Results of Operations and Financial Condition. On August 13, 2026, Candel Therapeutics, Inc. announced its financial results for the quarter ended June 30, 2026. The full text of the press release issued in connection with the announcement is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information in this Current Report on Form 8-K (including Exhibit 99.1 attached hereto) is furnished herewith and shall not be deemed “filed” for purposes of Section 18 of the Securities E…
Why it matters: Preparing for the launch shows they are ready to make money. It shows faith in the product.
Supportive ifThey shared big news about the launch of aglatimagene.
Worry ifNo updates or delays in launch preparations.
Why it matters: Submitting the BLA is important for making money from prostate cancer treatment. It shows progress in getting approval.
Supportive ifAnnouncement of the BLA submission for CAN-2409 in prostate cancer.
Worry ifNo submission or delay in the BLA process.
Why it matters: The BLA submission is a key step for potential approval and market entry. It signals progress in Candel's prostate cancer treatment efforts.
Supportive ifThe company submits the BLA for aglatimagene for prostate cancer by the end of Q4 2026.
Worry ifThe company delays the BLA submission beyond Q4 2026.
Why it matters: This data could show how well the drug works. It may help future clinical plans.
Watch forThe company will share good biomarker data in Q3 2026. This data shows aglatimagene works well.
Also watch forThe biomarker data in Q3 2026 shows no important findings or negative results.
A larger daily loss that occurred about once in every 20 trading days.
Deepest peak-to-trough drop in the last year.
| Measure | Value | Meaning |
|---|---|---|
| Typical day | ±$230 on $10,000 · ±2.3% | How much price usually moves either way. |
| Bad day | $647 loss on $10,000 · 6.5% | A larger daily loss that occurred about once in every 20 trading days. |
| Largest peak-to-trough drop in the past year | $3,252 loss on $10,000 · 32.5% | Deepest peak-to-trough drop in the last year. |
Past year. 1.00 means similar movement; 1.20 means about 20% more.
Past year. 1.00 means similar movement to the sector. This is secondary context.
Latest 30 trading days, shown as an annual percentage.
Latest 252 trading days, shown as an annual percentage.
20-trading-day average in US dollars.
Trading days used by the source risk snapshot.
Past results, not a forecast. Not investment advice.
Why it matters: Starting this trial is crucial for advancing the NSCLC program and could impact future revenue potential. It shows commitment to pipeline growth.
Supportive ifCandel announces the initiation of the phase 3 trial for CAN-2409 in NSCLC in June 2026.
Worry ifCandel postpones the start of the phase 3 trial for CAN-2409 in NSCLC.
Why it matters: Starting this trial is key for aglatimagene's market and wider use.
Supportive ifThe company starts the phase 3 trial of aglatimagene in NSCLC as planned.
Worry ifThe trial start is delayed or does not begin enrollment as planned.